Published in Psychiatr Serv on August 01, 2014
Sevoflurane for Treatment-Resistant Depression | NCT05008939
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J (2015) 0.94
12-month outcomes of community engagement versus technical assistance to implement depression collaborative care: a partnered, cluster, randomized, comparative effectiveness trial. Ann Intern Med (2014) 0.92
A shared framework for the common mental disorders and Non-Communicable Disease: key considerations for disease prevention and control. BMC Psychiatry (2015) 0.88
Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci (2015) 0.84
Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies. Mol Neuropsychiatry (2015) 0.82
Vagal Nerve Stimulation for Treatment-Resistant Depression. Neurotherapeutics (2017) 0.80
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry (2015) 0.79
e-CBT (myCompass), Antidepressant Medication, and Face-to-Face Psychological Treatment for Depression in Australia: A Cost-Effectiveness Comparison. J Med Internet Res (2015) 0.77
Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy. Front Psychiatry (2015) 0.77
Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. World J Biol Psychiatry (2016) 0.76
Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy. Depress Res Treat (2015) 0.76
Structural connectivity and response to ketamine therapy in major depression: A preliminary study. J Affect Disord (2015) 0.76
Experimental medication treatment approaches for depression. Transl Psychiatry (2017) 0.75
Mood Instability and Irritability as Core Symptoms of Major Depression: An Exploration Using Rasch Analysis. Front Psychiatry (2016) 0.75
Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy. J ECT (2016) 0.75
Medication-free Alternatives for Long-term Maintenance of Bipolar Disorder: A Case Series. Glob Adv Health Med (2015) 0.75
Deep brain stimulation in the bed nucleus of the stria terminalis and medial forebrain bundle in a patient with major depressive disorder and anorexia nervosa. Clin Case Rep (2017) 0.75
Transcranial Direct Current Stimulation: Considerations for Research in Adolescent Depression. Front Psychiatry (2017) 0.75
Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression. Amino Acids (2016) 0.75
Current Trends in Identifying Rapidly Acting Treatments for Depression. Curr Behav Neurosci Rep (2016) 0.75
Rodent models of treatment-resistant depression. Eur J Pharmacol (2014) 0.75
Transcranial low-level infrared laser irradiation ameliorates depression induced by reserpine in rats. Lasers Med Sci (2016) 0.75
Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(®)) to Guide Treatment of Patients with Depression and/or Anxiety. Pharmacoeconomics (2017) 0.75
Reward-Related Ventral Striatum Activity Buffers Against the Experience of Depressive Symptoms Associated with Sleep Disturbances. J Neurosci (2017) 0.75
The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence. Alcohol Clin Exp Res (2017) 0.75
An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women. J Clin Psychopharmacol (2017) 0.75
How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. Arch Pediatr Adolesc Med (2002) 2.51
Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost (2002) 2.16
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol (2002) 2.15
Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol (2006) 2.13
Training in psychiatric genomics during residency: a new challenge. Acad Psychiatry (2010) 1.67
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics (2012) 1.34
The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J Neurochem (2004) 1.30
Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. J Neurosci Methods (2004) 1.26
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol (2004) 1.16
De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int Psychogeriatr (2004) 1.13
Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics (2013) 1.12
Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging (2001) 1.12
A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med (2013) 1.10
Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry (2006) 1.08
Comparative effectiveness in personalized medicine-clearly defining the intended use population. Value Health (2013) 1.08
Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry (2013) 1.07
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol (2014) 1.07
Increased adult hippocampal brain-derived neurotrophic factor and normal levels of neurogenesis in maternal separation rats. J Neurosci Res (2005) 1.04
Pharmacogenomics of methylphenidate response: making progress. J Am Acad Child Adolesc Psychiatry (2009) 1.04
Sequence variations of the human MPDZ gene and association with alcoholism in subjects with European ancestry. Alcohol Clin Exp Res (2009) 1.03
Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther (2010) 1.02
CYP2D6: novel genomic structures and alleles. Pharmacogenet Genomics (2009) 1.01
The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opin Drug Metab Toxicol (2007) 0.98
Recent trends in american board of psychiatry and neurology psychiatric subspecialties. Acad Psychiatry (2011) 0.97
Genetic variability in the NMDA-dependent AMPA trafficking cascade is associated with alcohol dependence. Addict Biol (2011) 0.95
Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc (2007) 0.94
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol (2004) 0.94
Alcohol craving as a predictor of relapse. Am J Addict (2012) 0.94
Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit (2011) 0.91
Changes in heart rate variability associated with acute alcohol consumption: current knowledge and implications for practice and research. Alcohol Clin Exp Res (2011) 0.91
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics (2013) 0.90
Interaction of SLC6A4 and DRD2 polymorphisms is associated with a history of delirium tremens. Addict Biol (2010) 0.88
Functional role of the polymorphic 647 T/C variant of ENT1 (SLC29A1) and its association with alcohol withdrawal seizures. PLoS One (2011) 0.87
Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. Neuropharmacology (2012) 0.87
Metabolic alterations in medication-free patients with bipolar disorder: a 3T CSF-corrected magnetic resonance spectroscopic imaging study. Psychiatry Res (2007) 0.86
Prevention of tobacco use in adolescents: review of current findings and implications for healthcare providers. Curr Opin Pediatr (2002) 0.85
Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states. Int J Neuropsychopharmacol (2012) 0.85
Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol (2003) 0.84
Replication of genome wide association studies of alcohol dependence: support for association with variation in ADH1C. PLoS One (2013) 0.84
Altered expression of hippocampal dentate granule neuron genes in a mouse model of human 22q11 deletion syndrome. Schizophr Res (2006) 0.83
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol (2014) 0.83
Association of GATA4 sequence variation with alcohol dependence. Addict Biol (2012) 0.82
Changes in heart rate variability in response to treatment with electroconvulsive therapy. J ECT (2004) 0.81
A retrospective study of gender differences in depressive symptoms and risk of relapse in patients with alcohol dependence. Am J Addict (2013) 0.80
Gender differences in the relationship between depressive symptoms and cravings in alcoholism. Am J Addict (2010) 0.80
Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. The context of genetic testing in clinical psychiatric practice. CNS Spectr (2006) 0.79
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics (2010) 0.78
Prospectively assessed early life experiences in relation to cortisol reactivity in adolescents at risk for asthma. Dev Psychobiol (2012) 0.78
Novel directions in antipsychotic target identification using gene arrays. Curr Drug Targets CNS Neurol Disord (2002) 0.78
Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget (2012) 0.78
Cost-effectiveness of gene-expression profiling for tumor-site origin. Value Health (2013) 0.78
Relationship between FKBP5 polymorphisms and depression symptoms among kidney transplant recipients. Depress Anxiety (2011) 0.77
Psychiatric emergency department visits on full-moon nights. Psychiatr Serv (2005) 0.77
HTR2A gene-child abuse interaction and association with a history of suicide attempt among Caucasian depressed psychiatric inpatients. J Affect Disord (2013) 0.77
Attenuation of scopolamine-induced and age-associated memory impairments by the sigma and 5-hydroxytryptamine(1A) receptor agonist OPC-14523 (1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2[1H]-quinolinone monomethanesulfonate). J Pharmacol Exp Ther (2002) 0.77
Utilization of residential alcoholism treatment in bipolar disorder. Am J Addict (2010) 0.76
A new interaction between SLC6A4 variation and child abuse is associated with resting heart rate. Depress Anxiety (2010) 0.75
"Diminished" association between the serotonin transporter linked polymorphism (5HTTLPR) and body mass index in a large psychiatric sample. J Affect Disord (2013) 0.75
Does 5HTTLPR long allele prevent hospitalization? Test of Hardy-Weinberg equilibrium. Psychiatr Genet (2014) 0.75
Magnetic resonance spectroscopic studies of pediatric mood disorders: a selective review. Curr Opin Pediatr (2005) 0.75
Early Asthma Onset. Psychiatry (1994) 0.75
The ABPN Maintenance of Certification Program for psychiatrists: past history, current status, and future directions. Acad Psychiatry (2008) 0.75